Startups · Private company profile
KymaThera
KymaThera develops precision medicines for genetically defined diseases, led by K-1728, an oral pan-mutant selective PI3Kα inhibitor.
Private · Biotechnology · San Diego
Funding history
| Date | Round | Amount | Lead / notable investors |
|---|---|---|---|
| October 6, 2026 | Series B | $80M | Alta Partners (lead); Venrock, Foresite Capital, J. Wood Capital |
Amounts as reported in the linked articles (company-reported or press-reported, not audited).
Blitz findings
- K-1728 is designed to potently inhibit disease-driving mutations in both the kinase and helical domains of PI3Kα while sparing wild-type PI3Kα. — Source
- The company expects to begin patient dosing in a Phase 1 study in the fourth quarter of 2026, and says the financing is expected to fund development through initial clinical proof-of-concept. — Source
- KymaThera is initially developing K-1728 for HR+/HER2- breast cancer and for PI3Kα-driven vascular malformations. — Source
- In preclinical studies, K-1728 drove tumor regressions at low, once-daily doses in models harboring both mutation classes, with a wide preclinical therapeutic window. — Source
- The team took the molecule from internal discovery to a clinic-ready program in about two years since the 2024 Series A. — Source
Latest research
KymaThera's $80M Series B — A Pan-Mutant Bet on PI3Kα, Timed for the Clinic · November 4, 2026
Sources
- KymaThera's $80M Series B — A Pan-Mutant Bet on PI3Kα, Timed for the Clinic (BlitzLab research)
- KymaThera company announcement via PR Newswire, October 6, 2026 (Morningstar republication)
- Citybiz, October 6, 2026
- BioPharma Dive, October 7, 2026
- Pharmaceutical Technology, October 6, 2026
Research only — not investment advice. Private-company figures are company-reported or press-reported, not audited. BlitzLab scores blitzscaling strategy from public data.